Prophylactic antiviral therapy for hepatitis B virus surface antigen‐positive patients with diffuse large B‐cell lymphoma treated with rituximab‐containing chemotherapy

Autor: Yoko Inaguma, Eiichi Ohtsuka, Yukiyoshi Moriuchi, Kazuho Miyashita, Masashi Mizokami, Nobuhiko Yamauchi, Tadahiko Igarashi, Koji Izutsu, Hiroshi Gomyo, Nobuko Kubota, Ryuzo Ueda, Mio Kurata, Yoshiko Inoue, Yoshiko Atsuta, Rika Sakai, Norifumi Tsukamoto, Yoko Ushijima, Kisato Nosaka, Dai Maruyama, Sachiko Suzuki, Toshiki Uchida, Shinichiro Yoshida, Ilseung Choi, Shigeru Kusumoto, Go Yamamoto, Yasuhito Tanaka, Kensuke Kojima, Satoshi Ichikawa, Hideki Tsujimura
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
Cancer Research
HBsAg
medicine.disease_cause
Gastroenterology
rituximab
Antineoplastic Agents
Immunological
0302 clinical medicine
Japan
Liver Function Tests
Antineoplastic Combined Chemotherapy Protocols
B‐cell lymphoma
Medicine
Aged
80 and over
Incidence
antiviral prophylaxis
virus diseases
Lamivudine
Alanine Transaminase
Induction Chemotherapy
General Medicine
Entecavir
Middle Aged
Hepatitis B
Oncology
Vincristine
030220 oncology & carcinogenesis
Original Article
Female
Rituximab
Lymphoma
Large B-Cell
Diffuse
medicine.drug
Adult
Hepatitis B virus
medicine.medical_specialty
HBV reactivation
Antiviral Agents
03 medical and health sciences
Clinical Research
Internal medicine
Humans
Cyclophosphamide
Aged
Retrospective Studies
Hepatitis
Hepatitis B Surface Antigens
business.industry
Induction chemotherapy
Original Articles
HBsAg‐positive
medicine.disease
Survival Analysis
digestive system diseases
030104 developmental biology
Doxorubicin
Case-Control Studies
DNA
Viral
Prednisone
Virus Activation
business
Diffuse large B-cell lymphoma
Zdroj: Cancer Science
ISSN: 1349-7006
1347-9032
DOI: 10.1111/cas.14846
Popis: We conducted a nationwide retrospective analysis of 116 hepatitis B virus (HBV) surface antigen (HBsAg)‐positive patients with diffuse large B‐cell lymphoma (DLBCL) and 278 HBsAg‐negative patients with DLBCL, as a control cohort, who received rituximab‐containing regimens as an induction chemotherapy at 30 Japanese medical centers between January 2004 and December 2014. Hepatitis was defined as an absolute serum alanine aminotransferase (ALT) level of ≥100 U/L. HBV reactivation‐related hepatitis was defined as hepatitis with an absolute serum HBV DNA level of ≥3.3 log IU/mL or an absolute increase of ≥2 log compared with the baseline value. HBsAg‐positive patients were divided into three groups based on anti–HBV prophylactic therapy: no nucleos(t)ide analogue (non–NA, n = 9), lamivudine (LAM, n = 20), and entecavir (ETV, n = 87). The 4‐year cumulative incidence (CI) of hepatitis in HBsAg‐positive and HBsAg‐negative patients was 21.1% and 14.6% (P = .081), respectively. The 4‐year CI of HBV reactivation‐related hepatitis was higher in HBsAg‐positive patients than in HBsAg‐negative patients (8.0% vs 0.4%; P
Prophylactic use of entecavir reduced HBV‐related hepatitis and mortality in HBsAg‐positive DLBCL treated with R‐chemotherapy. The 4‐year overall survival rate in HBsAg‐positive DLBCL patients receiving prophylactic entecavir was similar to that in HBsAg‐negative DLBCL.
Databáze: OpenAIRE
Externí odkaz: